A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in human epidermal growth factor receptor 2 negative, hormone receptor-positive breast cancer patients with bone metastases

被引：0
|
作者：
Rugo, H. S.
Huang, L.
Petrenciuc, O.
Zaccarini, P.
Coleman, R. E.
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Bayer HealthCare, Whippany, NJ USA
[3] Bayer SpA, Milan, Italy
[4] Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-OT2-01-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-11
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer
    Yardley, D. A.
    Awada, A.
    Cortes, J.
    Burris, H. A.
    Peterson, A.
    Bhattacharya, S.
    Gianni, L.
    Miller, K.
    Winer, E.
    CANCER RESEARCH, 2013, 73
  • [32] Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer.
    Conte, P. F.
    Guarneri, V.
    Generali, D. G.
    Bottini, A.
    Bazzola, L.
    Piacentini, F.
    Artioli, F.
    Cagossi, K.
    Bisagni, G.
    Bagnalasta, M.
    Tagliafico, E.
    Barbieri, E.
    Cavanna, L.
    Ravaioli, A.
    D'Amico, R.
    Vicini, R.
    Frassoldati, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review
    Li, Junjie
    Wang, Zhonghua
    Shao, Zhimin
    CANCER MEDICINE, 2019, 8 (05): : 1943 - 1957
  • [34] Efficacy of Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 526 - 534
  • [35] Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Brufsky, Adam M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2015, 9 : 137 - 147
  • [36] Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study
    Yan, Min
    Bian, Li
    Hu, Xichun
    Zhang, Qingyuan
    Ouyang, Quchang
    Feng, Jifeng
    Yin, Yongmei
    Sun, Tao
    Tong, Zhongsheng
    Wang, Xiaojia
    Yao, Herui
    Zou, Jianjun
    Zhu, Xiaoyu
    Jiang, Zefei
    TRANSLATIONAL BREAST CANCER RESEARCH, 2020, 1
  • [37] Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
    Omori, Yukie
    Enatsu, Sotaro
    Cai, Zhihong
    Ishiguro, Hiroshi
    BREAST CANCER, 2019, 26 (05) : 652 - 662
  • [38] Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
    van der Poel, Henk
    EUROPEAN UROLOGY, 2019, 76 (05) : 705 - 706
  • [39] Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer
    Bachelot, Thomas
    Cottu, Paul
    Chabaud, Sylvie
    Dalenc, Florence
    Allouache, Djelila
    Delaloge, Suzette
    Jacquin, Jean-Philippe
    Grenier, Julien
    Bouvet, Laurence Venat
    Jegannathen, Apurna
    Campone, Mario
    Del Piano, Francesco
    Debled, Marc
    Hardy-Bessard, Anne-Claire
    Giacchetti, Sylvie
    Mouret-Reynier, Marie-Ange
    Barthelemy, Philippe
    Kaluzinski, Laure
    Mailliez, Audrey
    Legouffe, Eric
    Sephton, Matthew
    Bliss, Judith
    Canon, Jean-Luc
    Penault-Llorca, Frederique
    Lemonnier, Jerome
    Cameron, David
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (32) : 3699 - +
  • [40] Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
    Yukie Omori
    Sotaro Enatsu
    Zhihong Cai
    Hiroshi Ishiguro
    Breast Cancer, 2019, 26 : 652 - 662
12345